// App-Quantinova.ai

3551 : Modulation of autophagy: A phase II study of vorinostat (VOR) plus hydroxychloroquine (HCQ) vs regorafenib (RGF) in chemo-refractory metastatic colorectal cancer (mCRC).

Researchers

Presenter

  • Sukeshi Patel Arora

Principal Investigators

  • Laura LaNiel Tenner

  • John Sarantopoulos

  • Jay Larry Morris

  • Lisa Longoria

  • Qianqian Liu

  • Joel Michalek

  • Devalingam Mahalingam

Medical Centers

  • UT Health San Antonio Cancer Center, San Antonio, TX

  • Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio, San Antonio, TX

  • Northwestern University, Chicago, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • Cytokine

  • Circulating DNA

Drug/Treatment

  • Hydroxychloroquine

  • Regorafenib

  • Vorinostat

Outcome

  • Unknown

Study Design

  • Randomized

  • Cross Over

  • Controlled

Phase

  • II

Study Id's

  • NCT02316340

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved